ArticleWorld journal of urology2026

Comparative safety analysis of enfortumab vedotin and pembrolizumab: monotherapy vs. combination therapy insights from FDA adverse event reporting system data.

Jingwen Lin et al.PubMed ↗Publisher ↗

No numbers read from the abstract.